Budesonid ve formoterol etkileşimleri

At the primary analysis, increased incidences of fractures (28.6% vs 11.4%) and deaths (38.5% vs 35.5%) have been observed in patients who received abiraterone acetate plus a corticosteroid in combination with radium Ra 223 dichloride compared to patients who received placebo in combination with abiraterone acetate plus a corticosteroid. (Abirateron etiketi, Uyarılar ve önlemler)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Adalimumab etiketi, Kutulu uyarı)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Withhold INLYTA and avelumab or pembrolizumab, initiate corticosteroid therapy as needed, and/or permanently discontinue the combination for severe or life-threatening hepatotoxicity. (Aksitinib etiketi, Uyarılar ve önlemler)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

If differentiation syndrome is suspected, immediately initiate high-dose corticosteroids and hemodynamic monitoring until resolution. (Arsenik trioksit etiketi, Kutulu uyarı)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Inhaled beta agonist: salmeterol ↑ salmeterol Coadministration of salmeterol with REYATAZ is not recommended. (Atazanavir etiketi, İlaç etkileşimleri)

…intubation (endotracheal) 1 2 Asthma-related hospitalization (≥24-hour stay) 115 105 ICS = Inhaled Corticosteroid, LABA = Long-acting Beta2-adrenergic Agonist The pediatric safety trial included 6208 pediatric patients 4 to 11 years of age who received ICS/LABA (fluticasone propionate /salmeterol inhalation powder) or ICS (fluticasone propionate inhalation powder). (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Most patients with rheumatoid arthritis who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Barisitinib etiketi, Kutulu uyarı)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Paradoxical Bronchospasm and Upper Airway Symptoms As with other inhaled medications, budesonide and formoterol fumarate dihydrate can produce paradoxical bronchospasm, which may be life threatening. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Inhaled beta agonist : salmeterol ↑ salmeterol Co-administration of salmeterol and PREZISTA/ritonavir is not recommended. (Darunavir etiketi, İlaç etkileşimleri)

Inhaled beta agonist: salmeterol ↑ salmeterol Co-administration with salmeterol is not recommended and may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations, and sinus tachycardia. (Darunavir ve kobisistat etiketi, İlaç etkileşimleri)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (Dosetaksel etiketi, Uyarılar ve önlemler)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Avoid concomitant use of other drugs that are also associated with similar cardiac effects (e.g., amphetamines, other sympathomimetic agents, atropine, amoxapine, scopolamine, antihistamines, other anticholinergic agents, amitriptyline, desipramine, other tricyclic antidepressants). (Dronabinol etiketi, Uyarılar ve önlemler)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Inhaled Beta Agonist: salmeterol ↑ salmeterol Coadministration of salmeterol and GENVOYA is not recommended. (Elvitegravir, kobisistat, emtrisitabin ve tenofovir etiketi, İlaç etkileşimleri)

…(5.7) , Drug Interactions (7) , and Clinical Pharmacology (12.3) ]: Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin Antimycobacterials: rifampin, rifapentine Glucocorticoid (systemic): dexamethasone (more than a single-dose) Herbal Products: St John's wort ( Hypericum perforatum ) Proton Pump Inhibitors: e.g., dexlansoprazole, esomeprazole,… (Emtrisitabin, rilpivirin ve tenofovir etiketi, Kontrendikasyonlar)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Etanersept etiketi, Kutulu uyarı)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

The potentiation of sympathomimetic substances and related compounds by MAO inhibitors may result in hypertensive crises (see WARNINGS ). (Fenelzin etiketi, Kontrendikasyonlar)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

…intubation (endotracheal) 1 2 Asthma-related hospitalization (≥24-hour stay) 115 105 ICS = Inhaled Corticosteroid, LABA = Long-acting Beta2-adrenergic Agonist The pediatric safety trial included 6208 pediatric patients 4 to 11 years of age who received ICS/LABA (fluticasone propionate /salmeterol inhalation powder) or ICS (fluticasone propionate inhalation powder). (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Serious Asthma-Related Events – Hospitalizations, Intubations and Death Use of LABA as monotherapy (without ICS) for asthma is associated with an increased risk of asthma-related death [see Salmeterol Multicenter Asthma Research Trial (SMART) ]. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Inhaled beta-agonist: Salmeterol ↑ Salmeterol Concurrent administration of salmeterol with fosamprenavir calcium is not recommended. (Fosamprenavir etiketi, İlaç etkileşimleri)

Avoid the use of preparations, such as decongestants and local anesthetics, that contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines. (İmipramin etiketi, İlaç etkileşimleri)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (İnfliksimab etiketi, Kutulu uyarı)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Fluticasone: Coadministration of fluticasone propionate and ketoconazole is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects. (Ketokonazol etiketi, İlaç etkileşimleri)

Known Hypersensitivity or Idiosyncrasy to the Sympathomimetic Amines NUMBRINO is contraindicated in patients with a known history of hypersensitivity to cocaine or to the components of the nasal solution. (Kokain etiketi, Uyarılar ve önlemler)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Levotiroksin ve liyotironin etiketi, Kutulu uyarı)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

• Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6) , Drug Interactions (7.7) , and Overdosage (10) ] . (Liyotironin etiketi, Kutulu uyarı)

Moreover, cholesterol and other products of the cholesterol biosynthesis pathway are essential components for fetal development, including synthesis of steroids and cell membranes. (Lovastatin etiketi, Kontrendikasyonlar)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

WARNING: TERMINATION OF PREGNANCY Mifepristone is a potent antagonist of progesterone and cortisol via the progesterone and glucocorticoid (GR-II) receptors, respectively. (Mifepriston etiketi, Kutulu uyarı)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (Mitotan etiketi, Kutulu uyarı)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

None of the cases were considered life-threatening and all resolved either without treatment or with medication (antihistamines or glucocorticoids). (Moeksipril etiketi, Uyarılar)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

IF INITIATION OF AEROSOLIZED RIBAVIRIN FOR INHALATION SOLUTION, USP TREATMENT APPEARS TO PRODUCE SUDDEN DETERIORATION OF RESPIRATORY FUNCTION, TREATMENT SHOULD BE STOPPED AND REINSTITUTED ONLY WITH EXTREME CAUTION, CONTINUOUS MONITORING AND CONSIDERATION OF CONCOMITANT ADMINISTRATION OF BRONCHODILATORS (SEE WARNINGS ). (Ribavirin etiketi, Kutulu uyarı)

Antimycobacterials Rifampin Rifapentine Glucocorticoid (systemic) Dexamethasone (more than a single-dose treatment) Herbal Products St. (Rilpivirin etiketi, Kontrendikasyonlar)

Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (Roflumilast etiketi, Uyarılar ve önlemler)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Serious Asthma-Related Events – Hospitalizations, Intubations and Death Use of LABA as monotherapy (without ICS) for asthma is associated with an increased risk of asthma-related death [see Salmeterol Multicenter Asthma Research Trial (SMART) ]. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

In a multicenter clinical study, de novo renal transplant patients treated with sirolimus, mycophenolate mofetil (MMF), steroids, and an IL-2 receptor antagonist had significantly higher acute rejection rates and numerically higher death rates compared to patients treated with cyclosporine, MMF, steroids, and IL-2 receptor antagonist. (Sirolimus etiketi, Uyarılar ve önlemler)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (Somatropin etiketi, İlaç etkileşimleri)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Tofasitinib etiketi, Kutulu uyarı)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Tosilizumab etiketi, Kutulu uyarı)

Two of the four cases were life-threatening and resolved without treatment or with medication (corticosteroids). (Trandolapril etiketi, Uyarılar)

…(SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) tricyclic antidepressants other antidepressants, such as amoxapine, bupropion, maprotiline, nefazodone, trazodone, vilazodone, vortioxetine amphetamines and methylphenidates medicines that can raise blood pressure (sympathomimetic medicine), such as pseudoephedrine, phenylephrine and ephedrine. (Tranilsipromin etiketi, Kutulu uyarı)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin etiketi, Kutulu uyarı)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Upadasitinib etiketi, Kutulu uyarı)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Patients receiving concomitant corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) or anti-angiogenic agents, or patients with increasing age or who have an underlying history of gastrointestinal ulceration, underlying diverticular disease or bowel metastases may be at increased risk of perforation. (Afatinib etiketi, Uyarılar ve önlemler)

Sympathomimetics, Methylxanthines, Steroids In clinical studies, concurrent administration of aclidinium bromide and other drugs commonly used in the treatment of COPD including sympathomimetics (short-acting beta 2 agonists), methylxanthines, and oral and inhaled steroids showed no increases in adverse drug reactions. (Aklidinyum etiketi, İlaç etkileşimleri)

Risk of Neurologic Symptoms: Neurocysticercosis patients may experience cerebral hypertensive episodes, seizures or focal neurologic deficits after initiation of therapy; begin appropriate steroid and anticonvulsant therapy. (Albendazol etiketi, Uyarılar ve önlemler)

Institute appropriate medical management (e.g., glucocorticoids, epinephrine, meperidine) for infusion-related reactions as needed [see Dosage and Administration (2.2) ] . (Alemtuzumab etiketi, Uyarılar ve önlemler)

…osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (Alendronat etiketi, Uyarılar ve önlemler)

Patients who experience these effects, even without respiratory distress, require prolonged observation and appropriate monitoring measures since treatment with antihistamines and corticosteroids may not be sufficient to prevent respiratory involvement. (Aliskiren etiketi, Uyarılar ve önlemler)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs and isoniazid Alogliptin Cytochrome (CYP) P450, CYP-Substrates or Inhibitors Clinical Impact: Insulin Secretagogues and Insulin Insulin and insulin secretagogues… (Alogliptin ve metformin etiketi, İlaç etkileşimleri)

If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (Alpelisib etiketi, Uyarılar ve önlemler)

Corticosteroids and Corticotropin (ACTH) Concurrent use of corticosteroids and ACTH may potentiate hypokalemia, which could predispose the patient to cardiac dysfunction. (Amfoterisin B etiketi, İlaç etkileşimleri)

Diuretics: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Beta-blockers: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Diuretics: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

The chance is higher if you are age 60 or older take a blood thinning (anticoagulant) or steroid drug have 3 or more alcoholic drinks every day while using this product have had stomach ulcers or bleeding problems take more or for a longer time than directed take other drugs containing prescription or nonprescription NSAIDs [aspirin, ibuprofen, naproxen, or others]… (Aspirin etiketi, Uyarılar)

Beta-blockers: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Beta-blockers: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Albuterol (or other beta 2 agonists): Increase the frequency of monitoring blood pressure and heart rate. (Atomoksetin etiketi, İlaç etkileşimleri)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Aztreonam etiketi, Uyarılar ve önlemler)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Belladonna ve afyon etiketi, Uyarılar ve önlemler)

Diuretics: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

• Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (Benralizumab etiketi, Uyarılar ve önlemler)

Beta-blockers: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Corticosteroids (systemic): cortisone/hydrocortisone dexamethasone ↑ corticosteroids (systemic) ↓ lenacapavir (dexamethasone) Concomitant administration with systemic corticosteroids whose exposures are significantly increased by CYP3A inhibitors can increase the risk for Cushing's syndrome and adrenal suppression. (Biktegravir, emtrisitabin ve tenofovir alafenamid etiketi, İlaç etkileşimleri)

Beta-blockers: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Beta-blockers: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

Beta-blockers: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Diuretics: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Buprenorfin etiketi, Uyarılar ve önlemler)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Buprenorfin ve nalokson etiketi, Uyarılar ve önlemler)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Butorfanol etiketi, Uyarılar)

Eosinophilic pneumonia: Discontinue Daptomycin for Injection and consider treatment with systemic steroids. (Daptomisin etiketi, Uyarılar ve önlemler)

Closely monitor patients for signs of reduced effectiveness when deferasirox is administered with drugs metabolized by CYP3A4 (e.g., alfentanil, aprepitant, budesonide, buspirone, conivaptan, cyclosporine, darifenacin, darunavir, dasatinib, dihydroergotamine, dronedarone, eletriptan, eplerenone, ergotamine, everolimus, felodipine, fentanyl, hormonal contraceptive… (Deferasiroks etiketi, İlaç etkileşimleri)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (Denosumab etiketi, Uyarılar ve önlemler)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Sex hormone binding globulins are increased and result in elevated levels of total circulating sex steroids however, free or biologically active levels either decrease or remain unchanged. e. (Desogestrel ve etinilestradiol etiketi, Önlemler)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Diflunisal etiketi, Uyarılar)

Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (Digoksin etiketi, Uyarılar ve önlemler)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Diklofenak etiketi, Uyarılar ve önlemler)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Diklofenak ve misoprostol etiketi, Uyarılar ve önlemler)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids. (Disikloverin etiketi, İlaç etkileşimleri)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Drug Interactions Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect (see PRECAUTIONS, General ). (Doksapram etiketi, İlaç etkileşimleri)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Beta-blockers: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (Dupilumab etiketi, Uyarılar ve önlemler)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Diuretics: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Diuretics: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease may be at increased risk of perforation [see Adverse Reactions (6.1 , 6.2) ]. (Erlotinib etiketi, Uyarılar ve önlemler)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Beta-blockers: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Other binding proteins may be elevated in serum (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased total circulating corticosteroids and sex steroids, respectively. (Estradiol etiketi, Önlemler)

Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins [see Warnings and Precautions ( 5.11 ) and Drug Interactions ( 7.2 )]. (Estradiol ve dienogest etiketi, İlaç etkileşimleri)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (Estradiol ve noretisteron etiketi, Uyarılar ve önlemler)

Diuretics: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

The amount of both steroids should be considered in the choice of an oral contraceptive. (Etinodiol diasetat ve etinilestradiol etiketi, Uyarılar)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Etodolak etiketi, Uyarılar)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Corticosteroid : dexamethasone (systemic) ↓ etravirine Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. (Etravirin etiketi, İlaç etkileşimleri)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fenoprofen etiketi, Uyarılar ve önlemler)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fentanil etiketi, Uyarılar ve önlemler)

In both cases, the patients were taking a 1.25 mg dose of fingolimod (higher than the recommended 0.5 mg dose) and had received high-dose corticosteroid therapy to treat suspected MS relapses. (Fingolimod etiketi, Uyarılar ve önlemler)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking, use of alcohol, older age, and poor general health status. (Flurbiprofen etiketi, Uyarılar ve önlemler)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Diuretics: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Diuretics: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

…medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H 2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are… (Glimepirid etiketi, İlaç etkileşimleri)

…olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs. (Glipizid etiketi, İlaç etkileşimleri)

Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (Gliserol fenilbütirat etiketi, İlaç etkileşimleri)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Caution is advised when haloperidol decanoate is used in combination with drugs known to cause electrolyte imbalance (e.g., diuretics or corticosteroids) because hypokalemia, hypomagnesemia, and hypocalcemia are risk factors for QT prolongation. (Haloperidol etiketi, İlaç etkileşimleri)

Long-term treatment with steroids may be necessary (see PRECAUTIONS, Laboratory Tests ). (Hidralazin etiketi, Uyarılar)

Diuretics: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Hidrokodon etiketi, Uyarılar ve önlemler)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Hidrokodon ve homatropin etiketi, Uyarılar ve önlemler)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Hidrokodon ve ibuprofen etiketi, Uyarılar)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Hidrokodon ve parasetamol etiketi, Uyarılar)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Hidromorfon etiketi, Uyarılar ve önlemler)

…osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (İbandronat etiketi, Uyarılar ve önlemler)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (İbuprofen etiketi, Uyarılar ve önlemler)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (İbuprofen ve famotidin etiketi, Uyarılar ve önlemler)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Diuretics: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (İndometazin etiketi, Uyarılar ve önlemler)

…Insulin Aspart Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (İnsülin aspart etiketi, İlaç etkileşimleri)

…Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (İnsülin degludek etiketi, İlaç etkileşimleri)

…Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (İnsülin detemir etiketi, İlaç etkileşimleri)

…Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (İnsülin glarjin etiketi, İlaç etkileşimleri)

…Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (İnsülin lispro etiketi, İlaç etkileşimleri)

Diuretics: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Oral hydration, recumbency, intravenous normal saline, and/or parenteral corticosteroids have been used to treat postural hypotension. (İvermektin etiketi, Uyarılar)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Diuretics: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Beta-blockers: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Sympathomimetics and Vasopressin : Sympathomimetics and vasopressin may enhance the sympathomimetic effects of ketamine [see Drug Interactions ( 7.2 )] . (Ketamin etiketi, Uyarılar ve önlemler)

PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (Ketoprofen etiketi, Uyarılar ve önlemler)

In addition to past history of ulcer disease, other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids, or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Ketorolak etiketi, Uyarılar ve önlemler)

Diuretics: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (Kladribin etiketi, İlaç etkileşimleri)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Diuretics: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Diuretics: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Kodein etiketi, Uyarılar ve önlemler)

Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin (CBG), SHBG, leading to increased total circulating corticosteroids and sex steroids respectively. (Konjuge östrojenler etiketi, Önlemler)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (Konjuge östrojenler ve bazedoksifen etiketi, Uyarılar ve önlemler)

Beta-blockers: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients usually over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (Levofloksasin etiketi, Uyarılar ve önlemler)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Thyroid Hormone Replacement Therapy or Corticosteroid Replacement Therapy Clinical effect Concomitant use of CHCs with thyroid hormone replacement therapy or corticosteroid replacement therapy may increase systemic exposure of thyroid-binding and cortisol-binding globulin [see Warnings and Precautions (5.11) ]. (Levonorgestrel ve etinilestradiol etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Levorfanol etiketi, Uyarılar)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Failure to do so may precipitate an acute adrenal crisis when thyroid hormone therapy is initiated, due to increased metabolic clearance of glucocorticoids by thyroid hormone. (Levotiroksin etiketi, Uyarılar ve önlemler)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Diuretics: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Diuretics: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

In patients who experience mild or moderate IRRs, consider premedications, including antihistamines, corticosteroids, and antipyretics. (Margetuksimab etiketi, Uyarılar ve önlemler)

MPA Injectable Suspension, USP can pose an additional risk in patients with risk factors for osteoporosis (e.g., metabolic bone disease, chronic alcohol and/or tobacco use, anorexia nervosa, strong family history of osteoporosis or chronic use of drugs that can reduce bone mass such as anticonvulsants or corticosteroids). (Medroksiprogesteron etiketi, Uyarılar ve önlemler)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, anti-platelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs), smoking, use of alcohol, older age, and poor general health status. (Mefenamik asit etiketi, Uyarılar ve önlemler)

Laboratory evaluation for adrenal insufficiency and consideration of replacement or stress doses of a rapidly acting glucocorticoid are strongly recommended in such patients. (Megestrol etiketi, Uyarılar ve önlemler)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Meloksikam etiketi, Uyarılar ve önlemler)

Decrease corticosteroids gradually, if appropriate. (Mepolizumab etiketi, Uyarılar ve önlemler)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Metadon etiketi, Uyarılar ve önlemler)

Drug Interactions Methazolamide should be used with caution in patients on steroid therapy because of the potential for developing hypokalemia. (Metazolamid etiketi, İlaç etkileşimleri)

If not, corticosteroids may be given and other causes of anemia should be considered. (Metildopa etiketi, Uyarılar)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Metiltestosteron etiketi, Uyarılar)

This can be corrected by giving appropriate doses of corticosteroids. (Metirapon etiketi, Uyarılar ve önlemler)

Diuretics: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Beta-blockers: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Beta-blockers: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

NSAIDs, Aspirin, and Steroids: May elevate and prolong serum methotrexate levels and increase gastrointestinal toxicity. (Metotreksat etiketi, İlaç etkileşimleri)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (Moksifloksasin etiketi, Uyarılar ve önlemler)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Inhaled corticosteroid may be reduced gradually. (Montelukast etiketi, Uyarılar ve önlemler)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Morfin etiketi, Uyarılar ve önlemler)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Nabumeton etiketi, Uyarılar)

Beta-blockers: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Nalbufin etiketi, Uyarılar)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Naproksen etiketi, Uyarılar ve önlemler)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Naproksen ve esomeprazol etiketi, Uyarılar ve önlemler)

In Studies MS1 and MS2, an increase in infections was seen in patients concurrently receiving short courses of corticosteroids. (Natalizumab etiketi, Uyarılar ve önlemler)

Drugs and Herbals That May Reduce the Blood-Glucose-Lowering Effect of Nateglinide and Increase Susceptibility to Hyperglycemia Drugs: Thiazides, corticosteroids, thyroid products, sympathomimetics, somatropin, somatostatin analogues (e.g., lanreotide, octreotide), and CYP inducers (e.g., rifampin, phenytoin and St John's Wort). (Nateglinid etiketi, İlaç etkileşimleri)

Beta-blockers: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Nintedanib etiketi, Uyarılar ve önlemler)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (Ofloksasin etiketi, Uyarılar)

In multiple sclerosis (MS) clinical trials, all adult and pediatric patients who were treated with OCREVUS received premedication with methylprednisolone (or an equivalent steroid), and may have also received an antihistamine (all pediatric patients) and/or an analgesic/antipyretic to reduce the risk of infusion reactions prior to each infusion. (Okrelizumab etiketi, Uyarılar ve önlemler)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Oksaprozin etiketi, Uyarılar ve önlemler)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Oksikodon etiketi, Uyarılar ve önlemler)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Oksikodon ve parasetamol etiketi, Uyarılar ve önlemler)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Oksimorfon etiketi, Uyarılar ve önlemler)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Oliseridin etiketi, Uyarılar ve önlemler)

Diuretics: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Diuretics: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (Omalizumab etiketi, Uyarılar ve önlemler)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (Pamidronat etiketi, Uyarılar ve önlemler)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Parasetamol ve ibuprofen etiketi, Uyarılar ve önlemler)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Parasetamol ve kodein etiketi, Uyarılar)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (Pasireotid etiketi, Uyarılar ve önlemler)

Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (Penisilamin etiketi, Uyarılar)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Pentazosin ve nalokson etiketi, Uyarılar)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Petidin etiketi, Uyarılar ve önlemler)

Beta-blockers: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

…medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are… (Pioglitazon ve glimepirid etiketi, İlaç etkileşimleri)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Piroksikam etiketi, Uyarılar ve önlemler)

Prior and Concomitant Treatment with Anti-neoplastic, Immune-Modulating, or Immunosuppressive Therapies Anti-neoplastic, immune-modulating, or immunosuppressive therapies (including corticosteroids) should be coadministered with caution because of the risk of additive immune system effects [see Drug Interactions (7.1) ] . (Ponesimod etiketi, Uyarılar ve önlemler)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg on a weekly basis during therapy with budesonide and formoterol fumarate dihydrate. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

The following appear to be major risk factors for the development of these events: decreased oxygen delivery to tissues; serious neurological injury and/or sepsis; high dosages of one or more of the following pharmacological agents: vasoconstrictors, steroids, inotropes and/or prolonged, high-dose infusions of propofol (> 5 mg/kg/hour for > 48 hours). (Propofol etiketi, Uyarılar ve önlemler)

Beta-blockers: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

…Calcium Channel Blockers Diltiazem Decrease exposure Nifedipine Rifampin 1200 mg administered as a single oral dose 8 hours before administering a single oral dose of nifedipine 10 mg Decrease exposure Verapamil Decrease exposure Corticosteroids Numerous cases in the literature describe a decrease in glucocorticoid effect when used concomitantly with rifampin. (Rifampisin etiketi, İlaç etkileşimleri)

…Haloperidol Barbiturates Phenobarbital Benzodiazepines Diazepam Beta-Blockers Propranolol Calcium Channel Blockers Diltiazem, nifedipine, verapamil Cardiac Glycoside Preparations Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants… (Rifapentin etiketi, İlaç etkileşimleri)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (Risedronat etiketi, Uyarılar ve önlemler)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Therefore, for patients receiving both neuromuscular blocking agents (including Rocuronium Bromide Injection) and corticosteroids, the period of use of the neuromuscular blocking agent should be limited as much as possible and only used in the setting where in the opinion of the prescribing physician, the specific advantages of the drug outweigh the risk. (Rokuronyum etiketi, Uyarılar ve önlemler)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Salsalat etiketi, Uyarılar)

High concentrations of cefoxitin in the urine may interfere with measurement of urinary 17-hydroxy-corticosteroids by the Porter-Silber reaction, and produce false increases of modest degree in the levels reported. (Sefoksitin etiketi, Uyarılar ve önlemler)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants; or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Selekoksib etiketi, Uyarılar ve önlemler)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (Siprofloksasin etiketi, Uyarılar ve önlemler)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

These reactions include reversible corneal toxicity, and hemorrhagic conjunctivitis, which may be prevented or diminished by prophylaxis with a local corticosteroid eye drop; cerebral and cerebellar dysfunction, including personality changes, somnolence and coma, usually reversible; severe gastrointestinal ulceration, including pneumatosis cystoides intestinalis… (Sitarabin etiketi, Uyarılar)

Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

Valproic Acid, Haloperidol, or Corticosteroids : May increase plasma ammonia level; monitor ammonia levels closely. (Sodyum fenilbütirat etiketi, İlaç etkileşimleri)

Beta-blockers: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Diuretics: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Diuretics: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Sulindak etiketi, Uyarılar)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Sumatriptan ve naproksen etiketi, Uyarılar ve önlemler)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

The neuromuscular blocking effect of succinylcholine may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase [see Warnings and Precautions (5.9) ]. (Süksinilkolin etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Tapentadol etiketi, Uyarılar ve önlemler)

Diuretics: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (Temozolomid etiketi, Uyarılar ve önlemler)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (Temsirolimus etiketi, Uyarılar ve önlemler)

Dosage Increases: Increases in the dose of theophylline should not be made in response to an acute exacerbation of symptoms of chronic lung disease since theophylline provides little added benefit to inhaled beta2 -selective agonists and systemically administered corticosteroids in this circumstance and increases the risk of adverse effects. (Teofilin etiketi, Uyarılar)

Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (Teriparatid etiketi, Uyarılar ve önlemler)

Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin etiketi, İlaç etkileşimleri)

Abuse of Testosterone and Monitoring of Serum Testosterone : If testosterone use at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids is suspected, check serum testosterone concentration ( 5.5 ). (Testosteron etiketi, Uyarılar ve önlemler)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Beta-blockers: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (Tiotropium etiketi, İlaç etkileşimleri)

Drugs That Increase Catecholamines: Tolcapone did not influence the effect of ephedrine, an indirect sympathomimetic, on hemodynamic parameters or plasma catecholamine levels, either at rest or during exercise. (Tolkapon etiketi, İlaç etkileşimleri)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Tolmetin etiketi, Uyarılar)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Diuretics: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Tramadol etiketi, Uyarılar ve önlemler)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Tramadol ve parasetamol etiketi, Uyarılar ve önlemler)

Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Trastuzumab etiketi, Uyarılar ve önlemler)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Diuretics: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Diuretics: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Diuretics: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

More frequent INR monitoring should be performed when starting or stopping other drugs, including botanicals, or when changing dosages of other drugs, including drugs intended for short-term use (e.g., antibiotics, antifungals, corticosteroids) [ see Boxed Warning ]. (Varfarin etiketi, İlaç etkileşimleri)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care, including availability of fast‑acting bronchodilators. (Zanamivir etiketi, Uyarılar ve önlemler)

Prior to the first BIZENGRI infusion, premedicate with a corticosteroid, an H1 antihistamine and acetaminophen to reduce the risk of IRRs [see Dosage and Administration (2.4) ]. (Zenokutuzumab etiketi, Uyarılar ve önlemler)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (Zoledronik asit etiketi, Uyarılar ve önlemler)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid. (Akarboz etiketi, İlaç etkileşimleri)

If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplaz etiketi, Uyarılar ve önlemler)

Most patients with hypersensitivity pneumonitis discontinued treatment with ARIKAYCE and received treatment with corticosteroids [see Adverse Reactions (6.1) ] . (Amikasin etiketi, Uyarılar ve önlemler)

If paradoxical bronchospasm occurs following dosing with budesonide and formoterol fumarate dihydrate, it should be treated immediately with an inhaled, short-acting bronchodilator, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL should be discontinued immediately, and alternative therapy should be instituted. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (Ampisilin etiketi, Uyarılar)

Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. (Bempedoik asit etiketi, Uyarılar ve önlemler)

Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (Bevasizumab etiketi, Uyarılar ve önlemler)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (Bromokriptin etiketi, İlaç etkileşimleri)

The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan etiketi, Uyarılar)

Prednizon gibi kortikosteroidler kalsiyum emilimini azaltır ve D vitamini metabolizmasını bozarak kemik kaybına katkıda bulunur. (NIH Office of Dietary Supplements, Vitamin D)

These medications include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Dapagliflozin ve metformin etiketi, İlaç etkileşimleri)

Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

These would include diuretics, laxatives and supraphysiological use of steroid hormones with mineralocorticoid potential. (Droperidol etiketi, İlaç etkileşimleri)

Steroid hormones may be poorly metabolized in patients with impaired liver function. (Drospirenon ve etinilestradiol etiketi, Uyarılar ve önlemler)

When such an infection develops, it should be treated with appropriate local or systemic (i.e., oral antifungal) therapy while treatment with budesonide and formoterol fumarate dihydrate continues, but at times therapy with budesonide and formoterol fumarate dihydrate may need to be interrupted. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Empagliflozin ve metformin etiketi, İlaç etkileşimleri)

Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (Etonogestrel ve etinilestradiol etiketi, İlaç etkileşimleri)

Steroids may or may not be effective in controlling these hemolytic episodes. (Fludarabin etiketi, Uyarılar ve önlemler)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Glibenklamid etiketi, İlaç etkileşimleri)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Glibenklamid ve metformin etiketi, İlaç etkileşimleri)

These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Glipizid ve metformin etiketi, Önlemler)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glukagon etiketi, Uyarılar ve önlemler)

TREMFYA was subsequently discontinued, and the liver test abnormalities resolved following administration of corticosteroids [see Adverse Reactions (6.1) ] . (Guselkumab etiketi, Uyarılar ve önlemler)

If paradoxical bronchospasm occurs following dosing with budesonide and formoterol fumarate dihydrate, it should be treated immediately with an inhaled, short-acting bronchodilator, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL should be discontinued immediately, and alternative therapy should be instituted. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Corticosteroids A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption. (Kalsitriol etiketi, İlaç etkileşimleri)

Drug/Laboratory Interactions Quinine may produce an elevated value for urinary 17-ketogenic steroids when the Zimmerman method is used. (Kinin etiketi, İlaç etkileşimleri)

The use of prophylactic steroids (e.g., 100 mg/m 2 hydrocortisone on Days 1 through 3) may be of benefit in preventing signs or symptoms of SIRS or capillary leak syndrome. (Klofarabin etiketi, Uyarılar ve önlemler)

Elevated urinary steroid levels, varying degrees of electrolyte imbalance, hypovolemia, hemoconcentration, and hypoproteinemia may occur. (Klomifen etiketi, Uyarılar)

When such an infection develops, it should be treated with appropriate local or systemic (i.e., oral antifungal) therapy while treatment with budesonide and formoterol fumarate dihydrate continues, but at times therapy with budesonide and formoterol fumarate dihydrate may need to be interrupted. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

The recovery of the adrenal gland may take from days to months so patients should be protected from the stress (e.g., trauma or surgery) by the use of corticosteroids during the period of stress. (Kortikotropin etiketi, Uyarılar ve önlemler)

Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms. (Lenalidomid etiketi, Uyarılar ve önlemler)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Linagliptin ve metformin etiketi, İlaç etkileşimleri)

The infusion should be terminated immediately, followed by the administration of volume expanders, pressor agents, corticosteroids, or antihistamines at the discretion of the physician. (Melfalan etiketi, Uyarılar)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Metformin etiketi, İlaç etkileşimleri)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (Metimazol etiketi, Uyarılar)

Intra-arterial glucocorticoid injection at the site of injury, followed by systemic steroids. (Metoheksital etiketi, Uyarılar)

When such an infection develops, it should be treated with appropriate local or systemic (i.e., oral antifungal) therapy while treatment with budesonide and formoterol fumarate dihydrate continues, but at times therapy with budesonide and formoterol fumarate dihydrate may need to be interrupted. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Mitoksantron etiketi, İlaç etkileşimleri)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrekson etiketi, Uyarılar ve önlemler)

Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (Norelgestromin ve etinilestradiol etiketi, İlaç etkileşimleri)

Steroid hormones may be poorly metabolized in patients with impaired liver function. (Noretisteron ve etinilestradiol etiketi, Uyarılar ve önlemler)

Interactions with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (Norgestimat ve etinilestradiol etiketi, İlaç etkileşimleri)

Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (Norgestrel ve etinilestradiol etiketi, Önlemler)

If an allergic reaction occurs, the drug should be discontinued and the patient should receive supportive treatment, e.g. , artificial maintenance of ventilation, pressor amines, antihistamines, and corticosteroids. (Oksasilin etiketi, Uyarılar)

Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated. (Penisilin G etiketi, Uyarılar)

OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (Penisilin V etiketi, Uyarılar)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Pioglitazon ve metformin etiketi, İlaç etkileşimleri)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (Propiltiourasil etiketi, Uyarılar)

Other Concomitant Medications EVISTA can be concomitantly administered with ampicillin, amoxicillin, antacids, corticosteroids, and digoxin [see Clinical Pharmacology ( 12.3 )] . (Raloksifen etiketi, İlaç etkileşimleri)

In a study of patients with asthma whose bronchodilators were temporarily withheld for assessment, bronchoconstriction and wheezing following AFREZZA dosing was reported in 29% (5/17) and 0% (0/13) of patients with and without a diagnosis of asthma, respectively. (Regüler insülin (insan) etiketi, Uyarılar ve önlemler)

…antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (Repaglinid etiketi, İlaç etkileşimleri)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (Rituksimab etiketi, Uyarılar ve önlemler)

These medications include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Saksagliptin ve metformin etiketi, İlaç etkileşimleri)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (Sefadroksil etiketi, Uyarılar ve önlemler)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (Sefaklor etiketi, Uyarılar)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (Sefdinir etiketi, Uyarılar)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (Sefotetan etiketi, Uyarılar)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (Sefprozil etiketi, Uyarılar)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (Seftazidim etiketi, Uyarılar)

Serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures including oxygen, corticosteroids, intravenous fluids, intravenous antihistamines, pressor amines, and airway management, as clinically indicated. (Seftriakson etiketi, Uyarılar ve önlemler)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Sitagliptin ve metformin etiketi, İlaç etkileşimleri)

If symptoms of hypersensitivity occur, initiate appropriate therapy (e.g., antihistamines, corticosteroids, epinephrine). (Tenekteplaz etiketi, Uyarılar ve önlemler)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (Tobramisin etiketi, İlaç etkileşimleri)

If paradoxical bronchospasm occurs following dosing with budesonide and formoterol fumarate dihydrate, it should be treated immediately with an inhaled, short-acting bronchodilator, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL should be discontinued immediately, and alternative therapy should be instituted. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Patients improved with discontinuation of therapy and in certain cases administration of corticosteroids. (Ustekinumab etiketi, Uyarılar ve önlemler)

An open-label, nonrandomized clinical study examined the immune responsiveness to varicella vaccine in 243 asthma patients 12 months to 8 years of age who were treated with budesonide inhalation suspension 0.25 mg to 1 mg daily (n=151) or noncorticosteroid asthma therapy (n=92) (i.e., beta 2 -agonists, leukotriene receptor antagonists, cromones). (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

An open-label, nonrandomized clinical study examined the immune responsiveness to varicella vaccine in 243 asthma patients 12 months to 8 years of age who were treated with budesonide inhalation suspension 0.25 mg to 1 mg daily (n=151) or noncorticosteroid asthma therapy (n=92) (i.e., beta 2 -agonists, leukotriene receptor antagonists, cromones). (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Most patients improved promptly with adjunctive treatment with antihistamines or steroids and/or upon discontinuation of ziprasidone, and all patients experiencing these reactions were reported to recover completely. (Ziprasidon etiketi, Uyarılar ve önlemler)